ProMIS Neurosciences Inc.

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

PMN$3.98-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(expressed in US dollars)


· · Three Months Ended ·
· · March 31, ·
· · 2026 · · 2025 ·
Cash flows from operating activities
Net loss	$(8,244,372)	$(7,347,903)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	189,425	245,295
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(531,362)	337,919
Accounts payable	(826,591)	(537,301)
Accrued liabilities	(2,970,620)	2,375,124
Net cash used in operating activities	(12,383,520)	(4,926,866)

Cash flows from financing activities
Proceeds from issuance of Common Shares, pre-funded warrants, and common warrants from January 29, 2026 PIPE, net of issuance costs	70,081,309	—
Net cash provided by financing activities	70,081,309	—

Net increase (decrease) in cash	57,697,789	(4,926,866)

Cash at beginning of period	6,116,556	13,291,167
Cash at end of period	$63,814,345	$8,364,301

Noncash financing activities
Increase (decrease) in share-based compensation liability on CAD denominated share options (decreasing) increasing additional paid-in-capital	$50,198	$(86,163)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.